Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$22.9MCash on Hand
22.6mo Cash Runway
Follow YARW by emailGet an email when YARW reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about YARW, unsubscribe in one click. Privacy
📣 What YARW Says Is Next
second half of 2027 · “Topline data from the Phase 2a portion are expected in the second half of 2027.”
Company press release, Nov 12, 2026 · SEC filing
second half of 2027 · “Data from GenSci’s ongoing Phase 1 multiple ascending dose (“MAD”) trial in TED are anticipated in the second half of 2027 and are expected to inform the Company’s global TED development plans.”
Company press release, Nov 12, 2026 · SEC filing
second half of 2027 · “Topline results from the Phase 2a portion of the trial are expected in the second half of 2027.”
Company press release, Nov 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Earnings Reported Q3 2026 results: cash of $268.9 million as of September 30, 2026, expected to fund operations into 2030, with R&D expenses of $5.3 million, G&A of $5.5 million and a net loss of $9.7 million. Phase 2a topline data for YB-101 expected in the second half of 2027. Form 8-K · SEC filing · Press release
Sep 14, 2026 ·
Financing Yarrow Bioscience priced an underwriting of 5,769,231 common shares at $26.00 per share, and underwriters exercised in full their option for 865,384 more shares. Net proceeds are expected to be about $161.8 million, with closing expected September 14, 2026. Form 8-K · SEC filing
Sep 11, 2026 ·
Financing Yarrow Bioscience proposes a public offering of common stock and pre-funded warrants, with underwriters holding a 30-day option for additional shares. Offering amounts and price are left blank in this preliminary prospectus. The stock last traded at $29.11 on September 9, 2026. Form 424B5 · SEC filing
Sep 10, 2026 ·
Yarrow Bioscience posted an investor presentation and filed an update to its 10-K business section reflecting its merger with Yarrow Bioscience Operating Company Corp. The update does not change previously reported financial results. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 13, 2026 ·
Earnings Yarrow Bioscience filed an amended 8-K with recast financials for pre-merger Yarrow, including a net loss of $70,994 thousand from inception through December 31, 2025, driven by $70,000 thousand of acquired in-process R&D, and cash of $99,994 thousand at year-end 2025. Also furnished an updated corporate presentation. Form 8-K/A · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2027 · Phase 2 · Recruiting · Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
YARW holds $22.9M in cash and short-term investments (as of Jun 30, 2026) and burns about $3M/quarter from operations,
an estimated runway of 22.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:18 · Low
Cash runway 23 months +8
ATM program on file since Sep 2026 +15
Shelf registration (S-3, Mar 2024) +10
Company says cash lasts into 2030 -15We estimate that our existing cash and cash equivalents as of September 30, 2026 will be sufficient to enable us to fund operations into 2030, including completion of our Phase 2a/2b trial in patients with GD and preparatory work for our next planned TED study.10-Q, Nov 2026
Share count 15,234,944 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full YARW picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for YARW and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.